trial summary · NCT07900074
Mechanisms of Weight Loss: Tirzepatide vs Semaglutide
Mechanisms of Weight Loss Due to Dual GIP GLP-1 Receptor Agonism With Tirzepatide Compared to Semaglutide: A Randomized Controlled Trial
Trial record from the TrialBase DB dataset, status RECRUITING, condition Obesity (Disorder), sponsored by McMaster University. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
The goal of this clinical trial is to determine if there are differences in the effect of 12 weeks of tirzepatide versus semaglutide on energy balance in adults with obesity and without known diabetes. The main questions it aims to answer are: \- Does tirzepatide have a greater effect on energy expenditure or energy extraction than semaglutide? Participants will: * Take tirzepatide or semaglutide once weekly for 12 weeks * Undergo identical baseline and week 12 study visits (including 24-hour whole room indirect calorimeter testing, MRI scan, body composition, 3-day meal plan and stool collection)
Source record: https://clinicaltrials.gov/study/NCT07900074
Facts
| registry id | NCT07900074 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE4 |
| study type | INTERVENTIONAL |
| lead condition | Obesity (Disorder) |
| sponsor | McMaster University |
| sponsor class | OTHER |
| enrollment | 80 |
| start date | 2026-10-31 |
| primary completion | 2029-12-31 |
| completion | 2029-12-31 |
| results posted | not reported |
Conditions
- Obesity (Disorder)
Interventions
- Tirzepatide
- Semaglutide
Countries
- Canada
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.